1. Hypogonadism

Category Archives: Hypogonadism

Kallmann syndrome

Posted on by


Kallmann syndrome hypogonadotrophic hypogonadism
Kallmann syndrome is a form of hypogonadotrophic hypogonadism. A failure in the production of gonadotrophins (LH and FSH) from the pitutary gland results in ...

By: plymouthlad38

Continue reading here:

Kallmann syndrome

hypogonadism – Gheorghe Sarbu romanian scientist – panacea Corina – penis enlargement – Video

Posted on by


hypogonadism - Gheorghe Sarbu romanian scientist - panacea Corina - penis enlargement
http://www.sarbu.ro Gheorghe Sarbu presents oxiopatia therapy system, which is based on Corina panacea. With this product I was cured of lung cancer. Medical...

By: Mihai Danielescu

Read the rest here:

hypogonadism - Gheorghe Sarbu romanian scientist - panacea Corina - penis enlargement - Video

Pine Pollen Q

Posted on by


Pine Pollen Q A: How to Reverse Hypogonadism and Increase Testosterone Production
In this video Ryan from RAW Forest Foods addresses a common question: can Pine Pollen help correct hypogonadism. We answer that question, and talk about usin...

By: RAWForestFoods

Continued here:

Pine Pollen Q

Diagnostic Protocols and Alternative Treatment Options for Male Hypogonadism – Video

Posted on by


Diagnostic Protocols and Alternative Treatment Options for Male Hypogonadism
Presented at the 13th Clinical Applications for Age Management Medicine, November 2012, Las Vegas, NV Rethinking the Hypothalamic-Pituitary-Gonadal Axis Unde...

By: AgeManagmentMedicine

Read this article:

Diagnostic Protocols and Alternative Treatment Options for Male Hypogonadism - Video

Legitimate TRT user Dan Henderson pushing for Olympic-style drug testing in MMA

Posted on by

A cloud of suspicion hangs ominously over the heads of athletes in the UFC, their accomplishments viewed by many through the lens of performance-enhancing drug usage.

The use of PEDs is believed to be widespread throughout professional and high-level amateur sports, but even clean athletes whose accomplishments are the result of their athletic ability, hard work and perseverance, are tainted by the mess.

Little is done to stop the usage in combat sports. Postfight drug testing catches some users, but most experts say it nabs only those who don't understand how to mask their usage.

In fighting, there is no regularly scheduled regimen in which an athlete has to report his or her whereabouts to a testing agency in order to be randomly checked within 24 hours.

So, every time a fighter wins, there is plenty of suspicion that it involved artificial assistance. UFC middleweight contender Vitor Belfort is the latest to feel the backlash. Dan Henderson dodges a punch thrown by Lyoto Machida. (USA Today)

Since it was learned he's been on TRT, Belfort has scored several highlight-reel knockouts and become a legitimate title contender. He's been pressed about the issue so much that he suggested someone beat up the reporter asking about it, a thoughtless move for which he later apologized.

UFC light heavyweight Dan Henderson, who has had an exemption to use testosterone replacement therapy since 2007, said he believes there is a heavy amount of PED usage in the fight game.

"I think there is a decent amount [of PED usage in MMA]," said Henderson, a member of the 1992 and 1996 U.S. Olympic wrestling teams who will fight Rashad Evans in the main event of UFC 161 at the MTS Centre in Winnipeg on Saturday. "Just like at the top level of any sport, there is a decent amount of it. Guys look for that edge."

Henderson is one of a handful of fighters who have been given a therapeutic use exemption (TUE) to partake in testosterone replacement therapy (TRT). Henderson was diagnosed with hypogonadism, leading to his TUE

There are a number of causes of hypogonadism, or low testosterone, including previous steroid usage. Dr. Jonathan Gelber, an orthopedic surgeon who writes the Fight Medicine blog estimated that approximately 1 percent of the population between 18 and 40 who have not used anabolic steroids would be hypogonadal.

Read more:

Legitimate TRT user Dan Henderson pushing for Olympic-style drug testing in MMA

Mixed Martial Arts – Henderson pushing for Olympic-style drug testing in MMA

Posted on by

A cloud of suspicion hangs ominously over the heads of athletes in the UFC, their accomplishments viewed by many through the lens of performance-enhancing drug usage.

The use of PEDs is believed to be widespread throughout professional and high-level amateur sports, but even clean athletes whose accomplishments are the result of their athletic ability, hard work and perseverance, are tainted by the mess.

Little is done to stop the usage in combat sports. Post-fight drug testing catches some users, but most experts say it nabs only those who don't understand how to mask their usage.

In fighting, there is no regularly scheduled regimen in which an athlete has to report his or her whereabouts to a testing agency in order to be randomly checked within 24 hours.

So, every time a fighter wins, there is plenty of suspicion that it involved artificial assistance. UFC middleweight contender Vitor Belfort is the latest to feel the backlash.

Since it was learned he's been on TRT, Belfort has scored several highlight-reel knockouts and become a legitimate title contender. He's been pressed about the issue so much that he suggested someone beat up the reporter asking about it, a thoughtless move for which he later apologized.

UFC light heavyweight Henderson, who has had an exemption to use testosterone replacement therapy since 2007, said he believes there is a heavy amount of PED usage in the fight game.

"I think there is a decent amount [of PED usage in MMA]," said Henderson, a member of the 1992 and 1996 US Olympic wrestling teams who will fight Rashad Evans in the main event of UFC 161 at the MTS Centre in Winnipeg on Saturday. "Just like at the top level of any sport, there is a decent amount of it. Guys look for that edge."

Henderson is one of a handful of fighters who have been given a therapeutic use exemption (TUE) to partake in testosterone replacement therapy (TRT). Henderson was diagnosed with hypogonadism, leading to his TUE

There are a number of causes of hypogonadism, or low testosterone, including previous steroid usage. Dr. Jonathan Gelber, an orthopedic surgeon who writes the Fight Medicine blog estimated that approximately 1 percent of the population between 18 and 40 who have not used anabolic steroids would be hypogonadal.

See the original post:

Mixed Martial Arts - Henderson pushing for Olympic-style drug testing in MMA

BioSante Pharmaceuticals Receives NASDAQ Delisting Determination Letter

Posted on by

BAUDETTE, Minn.--(BUSINESS WIRE)--

BioSante Pharmaceuticals, Inc. (BPAX) announced today that on June 20, 2013, it received a letter from NASDAQ informing BioSante that, since the merger with ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. (ANI) constituted a business combination resulting in a change of control under Listing Rule 5110(a), BioSante was required to meet the initial listing criteria for the NASDAQ Global Market. The letter continued that, since BioSante did not meet the minimum $4 bid price requirement for initial listings under Listing Rule 5405(a)(1), NASDAQ had determined to delist BioSantes securities, and that BioSante could appeal this determination.

As part of its preparations for the merger, BioSante anticipated the delisting letter and intends to appeal the determination and request a hearing before the NASDAQ Hearings Panel. This hearing request, if made within the required timeframe, would mean that BioSantes securities remain listed at least until the panel renders its decision.

In the meantime, to address the bid price deficiency, the Company intends to hold, as soon as practicable, a special meeting of its stockholders to approve a reverse split of its common stock, among other matters. The purpose would be to increase the per share market price for the common stock to a level greater than the minimum $4 bid price in order to regain compliance with the NASDAQ Listing Rules.

Important Additional Information for Stockholders

This communication in this press release does not constitute a solicitation of any vote or approval. In connection with the proposed reverse split, BioSante is filing with the SEC a proxy statement, the definitive version of which will be sent to the stockholders of BioSante. Stockholders are urged to read the proxy statement (including any amendments or supplements) and other documents filed with the SEC carefully in their entirety when they become available because they will contain important information about BioSante and the proposed reverse split.

Stockholders will be able to obtain free copies of the proxy statement (when available) and other documents filed with the SEC on the SECs web site at http://www.sec.gov. Free copies of the proxy statement (when available) and other documents filed with the SEC also can be obtained by directing a request to BioSante, Attention: Investor Relations, telephone: (218) 634-3500. In addition, stockholders may access copies of the documents filed with the SEC by BioSante on BioSantes website at http://www.biosantepharma.com.

BioSante and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies in respect of the proposed reverse stock split. Information regarding BioSantes directors and executive officers is available in BioSantes joint proxy statement/prospectus filed with the SEC on May 8, 2013.

About BioSante and ANI

BioSante is an integrated specialty branded and generic pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals through its wholly-owned subsidiary, ANI. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173,000 square feet, ANI manufactures oral solid dose products, as well as liquids and topicals, including narcotics and those that must be manufactured in a fully contained environment due to their potency and/or toxicity. ANI also performs contract manufacturing for other pharmaceutical companies. Over the last two years ANI has launched three new products and has eleven products in development. ANIs targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. BioSantes other products include an FDA-approved testosterone gel for male hypogonadism, which is licensed to Teva Pharmaceuticals USA, Inc. For more information please visit our websites, http://www.biosantepharma.com and http://www.anipharmaceuticals.com.

Originally posted here:

BioSante Pharmaceuticals Receives NASDAQ Delisting Determination Letter


  1. Hypogonadism